Abiraterone: 10 agencies, 2012–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 13.8 years separate the first record, 17 Feb 2012 at AWMSG (Wales), from the most recent, 19 Nov 2025 at NICE (England).
TLV (Sweden) changed its position: not recommended on 31 May 2012, restricted by 19 Jun 2018, after a resubmission.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for abiraterone, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 3 of 27 records date from 2023 or later.
The programme is broad: 9 distinct indication wordings are recorded for abiraterone by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 27 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess abiraterone, on 17 Feb 2012; AIFA (Italy) did not open a file until 4 Apr 2020 — an unusually long tail of 8.2 years between the earliest and latest system to look at it.
The record arrives in waves: 9 separate years each carry two or more decisions, spread across 11 years in total.
9 of the 10 agencies here assessed abiraterone more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for abiraterone.
The full ledger for abiraterone reads 14 recommended, 4 restricted, 3 superseded and 2 not recommended, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 29 May 2025 | With prednisolone for the treatment of newly-diagnosed high-risk, metastatic hormone-sensitive prostate cancer (mHSPC) i… | superseded (limited) | source |
| HAS (France) | 4 Oct 2023 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2022 | Castration resistant metastatic carcinoma of the prostate | Not Recommended | source |
| AIFA (Italy) | 4 Apr 2020 | ZYTIGA è indicato insieme a prednisone o prednisolone per il trattamento del carcinoma metastatico della prostata ormono… | innovative status not granted · reimbursed class H | source |
| PHARMAC (New Zealand) | 13 Feb 2014 | Prostate cancer, metastatic, castrate-resistant | PTAC advice: Low · decision reached | source |
22 further decisions for abiraterone, across 10 agencies, are not shown here. They include the most recent record on file, 19 Nov 2025 from NICE (England); its outcome is in the subscriber dataset. They link to 18 further source documents.
Related molecules
- enzalutamide — same ATC class L02B — Endocrine therapy
- darolutamide — same ATC class L02B — Endocrine therapy
- apalutamide — same ATC class L02B — Endocrine therapy
- fulvestrant — same ATC class L02B — Endocrine therapy
- relugolix — same ATC class L02B — Endocrine therapy
- elacestrant — same ATC class L02B — Endocrine therapy
Coverage: 27 decisions for abiraterone from 10 agencies, 2012 to 2025. Data to 7 Sep 2026. ATC class L02B — Endocrine therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.